| Identification | Back Directory | [Name]
U-62066 (SPIRADOLINE MESYLATE) K-OPIOID AGONIST | [CAS]
87151-85-7 | [Synonyms]
Spiradoline
Spiradolinum
Espiradolina
U-62066 solid
Spiradolinum [latin]
Espiradolina [spanish]
Spiradoline mesylate salt
U-62066 (SPIRADOLINE MESYLATE) K-OPIOID AGONIST
Benzeneacetamide, 3,4-dichloro-N-methyl-N-[(5S,7R,8R)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-, rel-
(±)-(5α,7α,8β)-3,4-dichloro-n-methyl-n-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide mesylate salt
Benzeneacetamide, 3,4-dichloro-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)-, (5alpha,7alpha,8beta)-(+-)-
Spiradoline mesylate salt, (±)-(5α,7α,8β)-3,4-Dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide mesylate salt | [Molecular Formula]
C22H30Cl2N2O2 | [MDL Number]
MFCD00153876 | [MOL File]
87151-85-7.mol | [Molecular Weight]
425.39 |
| Chemical Properties | Back Directory | [storage temp. ]
2-8°C | [solubility ]
H2O: soluble14mg/mL | [form ]
solid | [color ]
white | [Water Solubility ]
H2O: 14mg/mL
methanol: insoluble | [InChIKey]
FHEZDPDAYTVKKG-JLBKCEDKSA-N | [SMILES]
CS(O)(=O)=O.CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)Cc4ccc(Cl)c(Cl)c4 |
| Hazard Information | Back Directory | [Uses]
Analgesic. | [Uses]
U 62066 is a selective κ-opioid agonist. It exhibits analgesic, diuretic and antitussive properties. | [Biological Activity]
U-62066also known as spiradolineis a highly selective K opioid receptor agonist. It exhibits analgesic and diuretic effects. Antitussive property of U-62066 is observed in rats. | [in vivo]
Spiradoline (U-62066; 0.1-0.4 mg/kg; subcutaneous injection; once; Sprague-Dawley rats) treatment dose-dependently reduces social behaviors in non-stressed adults, producing social avoidance at the highest dose tested, while younger animals displays reduced sensitivity to this socially suppressing effect of Spiradoline. In stressed animals, the socially suppressing effects of the Spiradoline are blunted at all ages, with juveniles and adolescents exhibiting increased social preference in response to certain doses of U-62066[1]. | Animal Model: | Juvenile, adolescent and adult Sprague-Dawley male and female rats exposured to repeated restraint[1] | | Dosage: | 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, and 0.4?mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Dose-dependently reduced social behaviors in non-stressed adults, producing social avoidance at the highest dose tested.
|
|
|
|